The FORCE will be with us! Anti-PD-1 (aka MK-3475) previously known as lambrolizumab, should be available for expanded use in as little as 3 months!
Our long, 2-day visit at the University of Iowa ended with great news – providing he has no growing brain mets, Kevin will be eligible for Anti-PD-1 in as few as 3 months, provided his current meds are no longer working. It’s expected that FDA approvals will follow 6 or so weeks after that, which means anyone can receive the drug, even if it’s not prescribed at a former clinical trial site.
Kevin received radiation for 2 lesions (I previously thought they found 2 and radiated 3, but I was wrong). These were tiny lesions, so hopefully his recovery will go fast and well. He has so far been awake all day, which is already an improvement over last time’s radiation.
The Mek/Tafinlar combination still seems to be working. Lesions system-wide are not gone, but they are smaller, and not progressing – all very good signs. The Anti-PD-1 news is the first news we’ve had that gives us hope Kevin will survive late stage melanoma. Imagine… he could be one of the first of many folks, ever, to do come back from such a serious diagnosis of melanoma.
Anti-PD-1, an immunotherapy drug, is not without its fair share of side effects, and it doesn’t work with everyone, so we’re not out of the woods yet – but this the best news we’ve heard yet, and something we’ve been hoping for.
Best of all, Anti-PD-1 will work with other cancers which have the PD-1 molecule on the service of T-cells such as kidney, lung cancer, and possibly breast, ovarian, colon, stomach, head and neck cancers as well. You can read more about Anti-PD-1 in this article.
Cancer is on the rise – right now 1 in 3 people will have some form of cancer in their lives. So, it pays to ask questions.
Did you know that many touted cancer cures work great in a petri dish, but not in a human body?
This is why there are clinical trials with set protocols to follow. Testing starts out in a petri dish, then move to mice or other animals, then to human trials. One of the questions that helped identify Anti-PD-1 was the fact that treatments often work in a dish, not in a body – so why? Investigating this question was partially how Anti-PD-1 was developed.
Cancer treatments can work or fail any step of the way of the clinical trial process. There are also cases where what works for a human being doesn’t have the same effect on an animal. Keep in mind, however, that successful treatments for animals will make their way to veterinary medicine – so animals do get some benefit from clinical trials as well.